Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,782.00
(
-0.06%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.56
(
-1.90%
)
Bitcoin
70,416.80
(
-1.16%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 171657

Friday, 06/27/2014 3:19:39 PM

Friday, June 27, 2014 3:19:39 PM

Post# of 257262
PFE/BMY—CHMP approves Eliquis for VTE treatment and secondary prevention:

http://in.reuters.com/article/2014/06/27/us-europe-medicine-pfizer-bristol-myers-idINKBN0F212720140627

In this same indication, Eliquis has an FDA PDUFA date of 8/24/14 (#msg-95178866).

Competitor, Xarelto has been approved for VTE treatment and secondary prevention in the US (#msg-81103054) and EU (#msg-80711606) since late 2012 and thus has a pretty big head start in this new indication for Eliquis.

Both drugs are approved in multiple jurisdictions for AF/stroke prevention and for primary VTE prevention following orthopedic surgery. Xarelto is also approved for ACS in the EU (#msg-88290069) but not the US (#msg-97335112).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now